Two skin treatments compared for UV-damaged skin

A strip of skin damaged by years of sun exposure carries more than visible lesions. At the cellular level, it holds clusters of mutated keratinocytes — clones that can, over time, become cancerous. Two of the most commonly used field treatments aim to clear that ground before it reaches that point.

The Journal of Investigative Dermatology published a study comparing topical 5-fluorouracil (5-FU) and photodynamic therapy (PDT) — both standard treatments for actinic keratoses and early skin cancers — examining how each performs at the molecular level, not only the visible surface.

What the treatments do

Both 5-FU and PDT target dysplastic keratinocytes within what dermatologists call the "field cancerization" region: an area of sun-damaged skin where precancerous mutations have already accumulated, the study explained. The goal of both is the same — reduce the carcinogenic potential of that tissue before it progresses.

The practical difference between them is significant for patients. PDT is administered in a clinical setting under controlled light exposure. 5-FU, by contrast, can be applied at home. That difference in delivery shapes which treatment clinicians recommend, according to the study, often based on convenience rather than a detailed comparison of their relative biological effects.

A gap in the evidence

Despite the frequency with which both treatments are prescribed, the study noted that direct comparison of their efficacy in reducing clonal mutations — the specific genetic changes that drive early UV-induced carcinogenesis — has been limited. The research set out to address that gap.

For people with albinism, who carry a substantially elevated lifetime risk of UV-induced skin damage, the distinction matters. Without melanin to absorb and scatter ultraviolet radiation, the skin accumulates photodamage at a rate that makes actinic keratoses a common and recurring concern rather than an occasional one. Field treatment — clearing wide areas of precancerous change, not just individual lesions — is often central to long-term skin management.

The study did not focus specifically on people with albinism, but its subject is directly relevant to the community. Understanding which treatment more thoroughly clears clonal mutations could inform more targeted conversations between patients and dermatologists about the most effective course of field therapy.

The Journal of Investigative Dermatology study represents one of the few direct molecular comparisons of two treatments that many people with albinism will encounter across their lifetimes.